tbuckley/cabot-search huggingface dataset:
STAT3 Is Activated By EBV in T or NK Cells Leading to Development of EBV-T/NK-Lymphoproliferative Disorders
Authors: Honami Komatsu, Ken-Ichi Imadome, Haruna Shibayama, Tomotaka Yada, Momoko Yamada, Kouhei Yamamoto, Takatoshi Koyama, Shigeyoshi Fujiwara, Osamu Miura, Ayako Arai
Journal: Blood (2014)
The Relevance of Anesthetic Drug–Induced Neurotoxicity
Authors: Tom G. Hansen, Thomas Engelhardt, Markus Weiss
Journal: JAMA Pediatrics (2016)

Preclinical studies1-3 in young animals have demonstrated neurodegeneration and subsequent neurocognitive impairment for virtually all clinically available general anesthetic drugs. However, comparative human studies on this issue are scarce and inconclusive.
OP0060-HPR Cross-Cultural Validation of The Systemic Sclerosis Quality of Life Questionnaire in Six European Countries: A Tool Validation Study: Table 1
Authors: M. Ndosi, B. Alcacer-Pitarch, Y. Allanore, F. Del Galdo, M. Frerix, S. García Díaz, F. Guidi, R. Hesselstrand, C. Kendall, M. Matucci-Cerinic, U. Müller-Ladner, G. Sandqvist, V. Torrente-Segarra, A. Redmond
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Systemic Sclerosis Quality of Life (SScQoL) questionnaire is a 29-item tool developed in UK to measure needs-based patient-reported quality of life in people with systemic sclerosis (SSc). <h3>Objectives</h3> To undertake a cross-cultural adaptation and validation of the SScQoL in six European countries. <h3>Methods</h3> This was a cross-sectional study involving six European countries: Germany, France, Italy, Spain, Sweden and UK. Adult patients with a definite diagnosis of SSc, who were willing and able to complete the SScQoL were eligible. The English SScQoL was adapted into the five European languages using a forward-backward translation process.<sup>1</sup> The translated SScQoL was completed by patients and the data was analysed using Rasch models. Where local response dependency was evident, items were grouped into subscales (function, emotion, sleep, social and pain) and re-analysed to test the scaling properties and cross-cultural equivalence, thus allowing calibration of the SScQoL into an interval scale. <h3>Results</h3> The adaptation of the SScQoL into European languages was seamless except in Germany, where patients reported problems in deciding yes/no responses for some items. Cross-cultural validation included 849 patients (mean age =57.9 years, SD =13.9), 87% of whom were women. All country-specific data except Germany had good fit to the Rasch model after correcting for local dependency. See table 1. After excluding Germany from the analysis, the scale was validated and calibrated with cross-cultural adjustment for Italy in the social subscale. <h3>Conclusions</h3> The SScQoL translated versions can be used as a valid common measure in France, Spain, Sweden, UK and Italy; the latter with adjustments in the social subscale. The German version requires further work. <h3>References</h3> Beaton DE, et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–91. <h3>Disclosure of Interest</h3> None declared
Infiltration of Effector Regulatory T Cells Is Associated with Poor Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Authors: Nakayama Shoko, Tsuji Motomu, Yokote Taiji, Akioka Toshikazu, Miyoshi Takuji, Hiraoka Nobuya, Hirata Yuji, Iwaki Kazuki, Takayama Ayami, Nishiwaki Uta, Masuda Yuki, Hatooka Jun, Hanafusa Toshiaki, Nishikawa Hiroyoshi
Journal: Blood (2015)
TET-dependent regulation of retrotransposable elements in mouse embryonic stem cells
Authors: Lorenzo de la Rica, Özgen Deniz, Kevin C. L. Cheng, Christopher D. Todd, Cristina Cruz, Jonathan Houseley, Miguel R. Branco
Journal: Genome biology (2016)

Ten-eleven translocation (TET) enzymes oxidise DNA methylation as part of an active demethylation pathway. Despite extensive research into the role of TETs in genome regulation, little is known about their effect on transposable elements (TEs), which make up nearly half of the mouse and human genomes. Epigenetic mechanisms controlling TEs have the potential to affect their mobility and to drive the co-adoption of TEs for the benefit of the host.We performed a detailed investigation of the role of TET enzymes in the regulation of TEs in mouse embryonic stem cells (ESCs). We find that TET1 and TET2 bind multiple TE classes that harbour a variety of epigenetic signatures indicative of different functional roles. TETs co-bind with pluripotency factors to enhancer-like TEs that interact with highly expressed genes in ESCs whose expression is partly maintained by TET2-mediated DNA demethylation. TETs and 5-hydroxymethylcytosine (5hmC) are also strongly enriched at the 5' UTR of full-length, evolutionarily young LINE-1 elements, a pattern that is conserved in human ESCs. TETs drive LINE-1 demethylation, but surprisingly, LINE-1s are kept repressed through additional TET-dependent activities. We find that the SIN3A co-repressive complex binds to LINE-1s, ensuring their repression in a TET1-dependent manner.Our data implicate TET enzymes in the evolutionary dynamics of TEs, both in the context of exaptation processes and of retrotransposition control. The dual role of TET action on LINE-1s may reflect the evolutionary battle between TEs and the host.
SAT0395 Statin Treatment in Patients with Ankylosing Spondylitis: Table 1
Authors: G. Wibetoe, E. Ikdahl, T.K. Kvien, S. Rollefstad, A.G. Semb
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid lowering therapy (LLT). <h3>Objectives</h3> We aimed to evaluate the effect of statins in AS patients and factors associated with the changes (Δ) in low-density lipoprotein cholesterol (LDL-c) and total cholesterol (TC). <h3>Methods</h3> In this longitudinal, observational study, 108 patients with AS underwent CVD risk evaluation. Of these, 48 patients had an indication for LLT and received statin treatment which was adjusted until lipid targets were achieved. Variables obtaining a p-value of &lt;0.25 in a univariate analyses were entered in forward, stepwise, linear regression models with ΔLDL-c and ΔTC as the dependent variables and were adjusted for age and gender, as well as baseline LDL-c levels (for ΔLDL-c) and intensity of LLT (for ΔTC). <h3>Results</h3> At first visit, median (IQR) age was 61.5 (56.0, 66.8) years, 72.9% were male, median disease duration was 27 (17.8, 32.8) years, 12.5% smoked daily, 70.8% had hypertension (HT), mean (SD) body mass index (BMI) was 26.0 (3.50) kg/m<sup>2</sup>, mean LDL-c and TC, were 3.82±1.02 and 6.04±1.16mmol/L and 70.8% had carotid plaque(s). Twenty patients were treated with low or moderate intensity LLT (simvastatin 20 mg or 40 mg, rosuvastatin &lt;40 mg or atorvastatin &lt;40 mg), while the remaining 28 received intensive LLT (rosuvastatin 40 mg or atorvastatin &gt;40 mg). LDL-c goals (50% reduction in LDL-c and /or LDL-c &lt;2.5 /&lt;1.8 mmol/L, for primary (n=10) or secondary prevention (n=38), respectively) were achieved in 85.4% of patients (90.0% and 84.2% for primary and secondary prevention, respectively). Reductions in LDL-c and TC were 1.60+0.41 mmol/L and 2.42+1.15 mmol/L (p&lt;0.001 for both). Predictive variables explaining 86.5% (R<sup>2</sup>) of the ΔLDL-c included erythrocyte sedimentation rate (ESR), established CVD and HT. Only ESR (p=0.03) and baseline LDL-c (p&lt;0.001) contributed significantly to the final model. ESR was inversely related to ΔLDL-c. In addition, higher baseline LDL-c levels were associated with larger LDL-c reduction. The final model for ΔTC, accounting for 33.0% (R<sup>2</sup>) of the variation, included ESR, waist circumference, BMI, non-steroidal anti-inflammatory drugs, and use of biologic and synthetic disease modifying anti-rheumatic drugs. Intensive LLT and high waist circumference were predictive of greater TC reductions (p=0.002 and 0.04, respectively). <h3>Conclusions</h3> Lipid lowering with statins was highly effective in AS patients. Inflammation measured by ESR was inversely related to change in LDL-c, possibly due to the suppressive effect on lipid levels. Further studies are needed to elucidate if the anti-inflammatory effect of rheumatic medication influence the lipid lowering effect of statins in patients with AS. <h3>Disclosure of Interest</h3> None declared
Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.
Authors: Kyriakos Papadopoulos, Alain Mita, Scott Antonio, Lionel D. Lewis, N.J. Reddy, Elizabeth Till, J.J. Mahany, Anne Keating, Amanda Seiz, Pamela Bartels, Anthony Tolcher
Journal: Blood (2007)
SP0036 The Role and Training Needs of Non-Medical Health Professionals Using Musculoskeletal Ultrasound for The Management of Patients with Rheumatic and Musculoskeletal Diseases
Authors: H. Siddle
Journal: Annals of the Rheumatic Diseases (2016)

The role of the non-medical health professional has advanced with many health professionals undertaking training and using musculoskeletal ultrasound (MSUS) to extend their scope of practice. Guidelines to support training for rheumatologists have been identified but currently there are not any recommendations to support the education and training needs of non-medical health professionals using MSUS. A EULAR Task Force was established to reach a consensus on the role and education and training needs of non-medical health professionals undertaking MSUS for the management of patients with rheumatic and musculoskeletal diseases (RMDs). Based on an extensive search of the literature and expert consensus seven points to consider were formulated encompassing the role and scope of health professionals using MSUS, including the application, feasibility and added value in daily practice, and the training and competency required by health professionals. The seven points to consider are intended to support the education and training needs for health professionals using MSUS to improve the management of patients with RMDs across Europe, in conjunction with local and national regulations. <h3>Disclosure of Interest</h3> None declared
Seasonal Malaria Chemoprevention: An Evolving Research Paradigm
Authors: Robert W. Snow
Journal: PLoS Medicine (2016)

In this issue, Paul Milligan and colleagues [1] provide evidence of the dramatic impact on the incidence of malaria of seasonal malaria chemoprevention (SMC) among children aged older than five years, the current recommended upper age limit for SMC.Research on drugs to prevent malaria in Africa among nonpregnant populations has a long history with surprisingly little sustainable policy impact.The last five years of SMC research signal an important stage in drug-based policy for malaria based on evolving field science. Antimalarial Drugs to Prevent Malaria in AfricaThe use of antimalarial drugs to prevent malaria in Africa is not new [2,3].At the turn of the last century, quininisation was widely promoted among residents of colonial administrative centres.During the "eradication" projects of the 1950s and 1960s, when indoor residual spraying failed to reach expected targets, mass drug administration (MDA) was included, resulting in huge reductions in infection incidence but never quite reaching elimination.The seasonal use of "chemoprophylaxis" was undertaken as part of pilot trials or elimination campaigns in Kenya, Burkina Faso, Senegal, Reunion, and Tunisia, again with dramatic impacts on parasite transmission and disease incidence [2,3].Approaches to the seasonal use of drugs to prevent infection were resurrected during the 1980s with trials of fortnightly distribution by village health workers of pyrimethamine-dapsone to young children in The Gambia, resulting in an 80% reduction in clinical events and a 34% reduction in all-cause childhood mortality [4].Trials during the early 2000s of intermittent presumptive sulphadoxine-pyrimethamine (SP) treatment of infants (IPTi) attending routine vaccine visits showed on average a 30% protection against morbid events due to malaria [5].However, with the exception of the presumptive SP treatment of malaria in pregnancy, throughout the history of malaria control in Africa, drug-based interventions have received less attention compared to vector control.All commentators, since the earliest use of quinine and chloroquine prophylaxis, have highlighted concerns related to adherence, adequate coverage, sustainability, delayed acquisition of immunity, and resistance, concerns relevant to both vector-and drug-based control.
Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single-Institution Report of 150 Cases
Authors: Katarina Sevcikova, Zuo Zhuang, Guillermo Garcia-Manero, Ricardo Alvarez, Hagop M. Kantarjian, Mego Michal, Constance Albarracin, Guilin Tang, Sara S. Strom, James M. Reuben, Joseph D Khoury
Journal: Blood (2014)
Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death Via Large Pore Formation
Authors: Shuji Matsuoka, Yasuyuki Ishii, Atsuhito Nakao, Hiroshi Masutani, Satoshi Takahashi, Yusuke Nakauchi, Okio Hino
Journal: Blood (2014)
FRI0122 Eular 2015 Recommendations for Cardiovascular Risk Could Radically Change Patients Care in Chronic Inflammatory Rheumatisms
Authors: C. Daien, A. Tubery, G. Du Cailar, T. Mura, M.C. Picot, R. Bourret, F. Roubille, J. Bousquet, J. Morel, P. Fesler, B. Combe
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with chronic inflammatory rheumatic disease have a greater risk of cardiovascular (CV) diseases. European recommendations of cardiology propose to classify patients with asymptomatic atheromatous plaques as high CV risk patients. New EULAR recommendations about CV risk management propose the use of supra-aortic vessel ultrasound for atheromatous plaques detection and total CV risk estimation. Moreover, EULAR-2015 recommendations suggest multiplying by a 1.5 factor the global CV risk for all patients with Rheumatoid Arthritis (RA) unlike 2010 recommendations. <h3>Objectives</h3> The objective of our study was to evaluate the impact of these new recommendations on CV management, especially on indication of statin use, in patients with RA in daily practice, in comparison to EULAR-2010 recommendations. <h3>Methods</h3> Total CV risk estimation included physical examination, glucidic and lipidic blood tests, supra-aortic and abdominal vessels ultrasound, echocardiography and global risk SCORE calculation. Heart-SCORE was multiplied according to EULAR-2010 (mSCORE2010) or EULAR-2015 (mSCORE2015) recommendations. For EULAR-2015 recommendations, patients with ultrasound carotid plaques were classified at high CV risk. LDL targets and immediate need of statin use were defined according to European cardiology recommendations with need of statin when LDL &gt;0.7 g/L for patients at very high CV risk and &gt;1 g/L for those at high risk. In moderate and low risk patients, statins are not immediately recommended. <h3>Results</h3> 157 RA patients underwent the screening with a mean disease duration of 13 (6–19) ± 9 years and mean age of 61 ± 11 years. 56/76 (73.7%) of patients classified as moderate risk with Heart-SCORE and 3/12 (25%) of patients with low risk had asymptomatic carotid plaques. Application of the EULAR 2010 recommendations should lead to immediate statin prescription in 42 patients (28%) whereas applications of the EULAR 2015 recommendations should lead to statin prescription in 92 (61%) patients. <h3>Conclusions</h3> In our experience, the use of carotid ultrasound to estimate total CV risk and thus to define LDL targets led to prescribe statins in 61% of patients with RA. <h3>Disclosure of Interest</h3> None declared
AB0234 Predictive Risk Factors of Remission and Low-Disease Activity in Rheumatoid Arthritis Patients Treated with Anti-TNF Drugs in Real Practice: Results from A Single Centre
Authors: P. Conigliaro, M. Tonelli, P. Triggianese, M.S. Chimenti, F. Sunzino, R. Perricone
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The goals of treatment in Rheumatoid Arthritis (RA) are remission and low disease activity (LDA); therefore, it is important to identify reliable predictive factors of these targets so that treatment can be tailored. <h3>Objectives</h3> We aimed at identifying positive and negative predictive factors of remission and LDA in RA patients treated in real practice with first line anti-TNF drugs. <h3>Methods</h3> Retrospective analysis of DAS28 remission/LDA in 308 RA patients treated for two years with first line anti-TNF drugs from January 2008 to December 2014: [female n=251 (81.5%), age 55±13 years, disease duration 7.6±8.4 years, rheumatoid factor (RF, n=220 (71.4%)), anti-citrullinated antibodies (ACPA, n=214 (69.5%)), baseline C-reactive protein (CRP, 11.4±16.5 (mg/L)), baseline DMARDs (n=225 (73.1%)), baseline steroid (n=160 (51.9%)), Adalimumab (n=109 (35.4%)), Etanercept (n=177 (57.5%)), other anti-TNF (n=22 (7.1%))]. Predictive factors considered for achievement of remission and LDA were: gender, age at the time of anti-TNF treatment (cut-off &gt;54 yrs old, n=139 (45.1%)), age at onset &gt;65 yrs old (n=27 (8.8%)), early arthritis (n=99 (32.1%)), baseline negative CRP (n=150 (48.7%), RF/ACPA positivity, good/moderate EULAR response at 6 months (n=169 (54.9%)), presence of any comorbidity (n=210 (68.2%)), cardiovascular comorbidity (n=83 (26.9%)), metabolic syndrome (n=26 (8.4%)), infectious (n=49 (15.9%)), thyreopathies (n=64 (20.8%)), concomitant DMARDs/steroid treatment. Intention to treat, ROC-curve, univariate and multivariate analysis by logistic regression were performed. Selection of the variables to be included in the multivariate analysis was performed on the basis of their statistical significance in the univariate analysis. <h3>Results</h3> In the univariate analysis positive predictors of remission and LDA at 6 months, 1 year and 2 years of anti-TNF treatments were identified as follows (Figure 1A): male gender, age at the time of anti-TNF treatment &lt;54 yrs old, age at onset &lt;65 yrs old, early arthritis, baseline negative CRP levels, good/moderate EULAR response at 6 months and concomitant DMARDs treatment. Negative predictors were presence of any comorbidity, cardiovascular comorbidity and metabolic syndrome. In the multivariate analysis the only significant positive predictor of remission and LDA at 6 months, 1 and 2 years of treatment was the negative CRP levels at baseline (Figure 1B). <h3>Conclusions</h3> Negative CRP levels prior to commence anti-TNF treatments in RA patients appeared to be a reliable predictor of remission and LDA in clinical practice. <h3>Disclosure of Interest</h3> None declared
Probability of Finding a Matched Unrelated Donor for An Asian Indian Patient Who Needs a Stem Cell Transplant.
Authors: Mammen Chandy, Alok Srivastava, Vikram Mathews, Biju George, Auro Vishwabandhya, Rachael Ryan, Katie Paulson, Daniel J. Weisdorf, Martin Maiers, Monika Fuessel, Kavitha M Lakshmi, Shanthi M, Dolly Daniel
Journal: Blood (2009)
H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences
Authors: Matthias Drosten, Lucía Simón-Carrasco, Isabel Hernández-Porras, Carmen G. Lechuga, María T. Blasco, Harrys K.C. Jacob, Salvatore Fabbiano, Nicoletta Potenza, Xosé R. Bustelo, Carmen Guerra, Mariano Barbacid
Journal: Cancer Research (2016)

Abstract Genetic studies in mice have provided evidence that H-Ras and K-Ras proteins are bioequivalent. However, human tumors display marked differences in the association of RAS oncogenes with tumor type. Thus, to further assess the bioequivalence of oncogenic H-Ras and K-Ras, we replaced the coding region of the murine K-Ras locus with H-RasG12V oncogene sequences. Germline expression of H-RasG12V or K-RasG12V from the K-Ras locus resulted in embryonic lethality. However, expression of these genes in adult mice led to different tumor phenotypes. Whereas H-RasG12V elicited papillomas and hematopoietic tumors, K-RasG12V induced lung tumors and gastric lesions. Pulmonary expression of H-RasG12V created a senescence-like state caused by excessive MAPK signaling. Likewise, H-RasG12V but not K-RasG12V induced senescence in mouse embryonic fibroblasts. Label-free quantitative analysis revealed that minor differences in H-RasG12V expression levels led to drastically different biological outputs, suggesting that subtle differences in MAPK signaling confer nonequivalent functions that influence tumor spectra induced by RAS oncoproteins. Cancer Res; 77(3); 707–18. ©2016 AACR.
CCAAT/Enhancer Binding Protein Epsilon Mediates Nicotinamide-Enhanced Clearance of Staphylococcus Aureus Infection
Authors: Nils H. Thoennissen, Pierre Kyme, Ching Wen Tseng, Gabriela B. Iwanski, Kenichi Shimada, Utz O Krug, Adrian Gombart, H. Phillip Koeffler, George Y. Liu
Journal: Blood (2010)
Should adults take vitamin D supplements to prevent disease?
Authors: Mark J Bolland, Alison Avenell, Andrew Grey
Journal: BMJ (2016)

#### What you need to know The US Preventive Services Task Force recommends against vitamin D and calcium supplementation for fracture prevention in otherwise healthy postmenopausal women.1 However, despite high quality systematic reviews reporting ineffectiveness, many guideline groups continue to recommend vitamin D supplementation (with or without calcium) for fall or fracture prevention. Recently Public Health England recommended that everyone needs vitamin D equivalent to an average daily intake of 10 μg (400 IU) to protect bone and muscle health,2 and more than 30-50% of older people in some Western countries take vitamin D supplements.3 4 The role of vitamin D supplementation in individuals not at high risk of osteomalacia (box 1) has been extensively investigated in recent years, but some uncertainties remain. #### BOX 1: Vitamin D facts
Letter by Venema et al Regarding Article, “Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled Trial”
Authors: Esmee Venema, Hester F. Lingsma, Diederik W.J. Dippel
Journal: Circulation (2016)
In vitro characterization and in vivo ultrasound molecular imaging of nucleolin-targeted microbubbles
Authors: Hua Zhang, Elizabeth S. Ingham, M. Karen J. Gagnon, Lisa M. Mahakian, Jingfei Liu, Josquin L. Foiret, Juergen K. Willmann, Katherine W. Ferrara
Journal: Biomaterials (2016)